Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study

American Journal of Psychiatry

Volumn 160, Issue 2, 2003, Pages 371-373

  Raskind, Murray A ^a   Peskind, Elaine R ^b   Kanter, Evan D ^b   Petrie, Eric C ^b   Radant, Allen ^b   Thompson, Charles E ^b   Dobie, Dorcas J ^b   Hoff, David ^b   Rein, Rebekah J ^b   Straits Tröster, Kristy ^b   Thomas, Ronald G ^b   McFall, Miles M ^b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PRAZOSIN; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AROUSAL; ARTICLE; AVOIDANCE BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HUMAN; MALE; NIGHTMARE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RATING SCALE; SOLDIER; SYMPTOM; TREATMENT OUTCOME; COMPARATIVE STUDY; DREAM; DRUG EFFECT; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; VETERAN;

ADRENERGIC ALPHA-ANTAGONISTS; COMBAT DISORDERS; CROSS-OVER STUDIES; DREAMS; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PRAZOSIN; PSYCHIATRIC STATUS RATING SCALES; SLEEP DISORDERS; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT OUTCOME; VETERANS;

EID: 0037315260     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.160.2.371     Document Type: Article

References (15)

1. Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER: The alpha-1 adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder. J Clin Psychiatry 2000; 61:129-133
2. Taylor F, Raskind MA: The alpha-1 adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22:82-85
3. Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, McFall ME, Peskind ER: Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry 2002; 63:565-568
4. Hieble JP, Ruffulo RR Jr: The use of alpha-adrenoreceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res 1996; 33:145-160
5. Geracioti TD Jr, Baker DG, Ekhator NN, West SA, Hill KK, Bruce AB, Schmidt D, Rounds-Kugler B, Yehuda R, Keck PE Jr, Kasckow JW: CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry 2001; 158:1227-1230
6. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM: The development of a Clinician-Administered PTSD Scale. J Trauma Stress 1995; 8:75-90
7. Laska EM, Klein DF, Lavori PW, Levine J, Robinson DS: Design issues for the clinical evaluation of psychotropic drugs, in Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. Edited by Prien RF, Robinson DS. New York, Raven Press, 1994, pp 29-68
8. Physicians' Desk Reference, 56th ed. Montvale, NJ, Medical Economics, 2002, pp 2699-2700
9. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
10. Penava SJ, Otto MW, Pollack MH, Rosenbaum JF: Current status of pharmacotherapy for PTSD: an effect size analysis of controlled studies. Depress Anxiety 1997; 4:240-242
11. Woodward SH, Arsenault NJ, Murray C, Bliwise DL: Laboratory sleep correlates of nightmare complaint in PTSD inpatients. Biol Psychiatry 2000; 48:1081-1087
12. Pickworth WB, Sharpe LG, Nozaki M, Martin WR: Sleep suppression induced by intravenous and intraventricular infusions of methoxamine in the dog. Exp Neurol 1977; 57:999-1011
13. Vynthilingam M, Anderson GM, Owens MJ, Halaszynski TM, Bremner JD, Carpenter LL, Heninger GR, Nemeroff CB, Charney DS: Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. J Clin Endocrinol Metab 2000; 85:4138-4145
14. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS: Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997; 154:624-629
15. Arnsten AF, Mathew R, Ubrian R, Taylor JR, Li BM: Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry 1999; 45:26-31